Molbio Diagnostics Limited share price

NSE: MOLBIO · ISIN INE869T01028

Key numbers

Market cap
₹ 14,359 Cr
Current price
₹ 1,246.00
52-week high / low
₹ 1,687 / 926
Stock P/E
57.8
Book value
₹ 103.7
Dividend yield
0.00%
ROCE
19.2%
ROE
15.6%
Debt to equity
0.38
Sales growth (3 yrs)
63.7%
Profit growth (3 yrs)
-
1-year return
-

About Molbio Diagnostics Limited

Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer, cholera, leprosy, etc.; and Truenat assays. The company was incorporated in 2000 and is based in Verna, India.

Concall summary (2026-09-12)

AI summary of the earnings call transcript · tone: Positive · source document

Guidance & outlook

  • As you can see, the annual R&D investment has increased from ₹598 million in FY24 to more than ₹2.16 billion over the last 3 years.
  • We sold 164 devices and 62.4 lakh kits in Q1 FY27.

Growth & demand

  • And this company, over a period of 27 years, grew to be the largest diagnostic manufacturing company in India and the largest exporter of diagnostics.
  • Yes, so R&D, we generally spend 5% to 6% of our revenue on R&D, and we'll continue to do the same as we saw that innovation led by R&D is kind of a key growth engine for us.

Margins & costs

  • Our EBITDA was ₹104 crores, which represents a margin of 25% of our revenues.
  • But from overall perspective, we would urge you to track us on an annual basis, and from a guidance perspective, we are looking to grow this year in terms of our top line at roughly about 25%, and we're looking to deliver an EBITDA of about 24% to 25%.

Capex & expansion

  • And so, therefore, the limited point here is with minimal capex, we will actually be able to grow our top line 2x from where we are today.
  • We hold a 70% stake here, which we acquired in 2023 and increased our stake from about 64% to 70% in 2025.

Balance sheet & cash

  • On the balance sheet front, we continue to remain efficient on our collections and working capital.
  • Our trailing 12-month receivable days are 87 days in June versus 86 days in March, and our trailing 12-month inventory days are 230 days in June versus 280 days in March.

Peers in Medical Devices

Data for information only, not investment advice. Prices end of day.